BioSpace News Archive

Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints Statistical Significance Achieved for Key Secondary Endpoint of Ocular Redness Statistical Significance Achieved for Secondary Endpoints of Ocular Tearing and Total Ocular Severity Score

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that senior members of the executive team will be participating at the following two investor conferences:

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the first quarter ended March 31, 2021.

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare, neurological disorders who have unmet medical needs, today announced that it will issue a press release on the Company’s first quarter 2021 financial results on Tuesday, May 11, 2021 at 8:00 a.m. ET.

LeMener will serve as senior external liaison between Southwestern Health Resources and the physician community

GoodRx, America’s leading resource for healthcare savings, announced an integrated offering with global biopharmaceutical company Sanofi to streamline patient access to Sanofi discounts.

A recently published study from an EU-funded project[i] demonstrates that the prebiotic enrichment of infant formula milk with BENEO’s oligofructose-enriched inulin reduces the duration of infections in the first year of a baby’s life.

DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration,

Results of a survey co-sponsored by PMD Alliance and Adamas showed the need for education in the Parkinson’s community about OFF time and dyskinesia

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol ® Cyclo™ in Niemann-Pick Type C1 Patient enrollment on track to commence in Q2 2021 Global clinical protocol agreed with US Food and Drug Administration (FDA) and European Medicines Agency (EMA)